Brigatinib, capmatinib, crizotinib, dacomitinib, erlotinib, lorlatinib and selpercatinib are now listed in the interaction checker as cancer drugs and interactions can be found with all comedications.
- Brigatinib (Alunbrig®) is an ALK tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
- Capmatinib (Tabrecta®) is a HGFR tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
- Crizotinib (Xalkori®) is an ALK tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
- Dacomitinib (Vizimpro®) is an EGFR tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
- Erlotinib (Tarceva®) is an EGFR tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
- Lorlatinib (Lorbena®, Lorviqua®) is an ALK tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
- Selpercatinib (Retevmo®) is a RET+ tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer and medullary thyroid cancer.
